SCHEMBL15420195

SCHEMBL15420195

CCS(=O)(=O)NC1CCOCC1COc1ccc(-c2nc(C)cs2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 2/20 0.38
AOC3 Q16853 2/20 0.38
GRM5 P41594 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PPARA Q07869 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 2/20 0.35
ADAM17 P78536 1/20 0.34
LMNA P02545 2/20 0.34
ADORA2A P29274 1/20 0.34
MAPK1 P28482 1/20 0.34
TGFBR1 P36897 1/20 0.34
PPARD Q03181 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
XDH P47989 1/20 0.33
CDC25A P30304 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15441583 1.00 AVPR1B (0.38) AVPR1BAOC3GRM5RAB9ANPC1
SCHEMBL15441274 0.85 LMNA (0.43) RAB9ANPC1SMN1; SMN2MAPTHPGD
SCHEMBL15420125 0.85 LMNA (0.43) RAB9ANPC1SMN1; SMN2MAPTHPGD
SCHEMBL15441099 0.85 CHRM1 (0.38) ALDH1A1
SCHEMBL15420420 0.85 CHRM1 (0.38) ALDH1A1
SCHEMBL15441182 0.84 P2RX3 (0.41)
SCHEMBL15420753 0.84 P2RX3 (0.41)
SCHEMBL15441632 0.83 GABRA1 (0.36) ADAM17XDH
SCHEMBL15420626 0.83 GABRA1 (0.36) ADAM17XDH
SCHEMBL15441667 0.82 LMNA (0.39) AVPR1BRAB9ANPC1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 AVPR1B 306/4885AOC3 3378/4885GRM5 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.